Magnetic properties and critical behaviors of the nodal-line semimetal candidate ErIn3.

The AuCu3-type intermetallic compoundsReIn3(Re= a rare earth ion) with type-IV magnetic space groups are predicted to show topologically nontrivial electronic states. Here, we grow ErIn3single crystals, and study their magnetic properties and critical behaviors by means of the magnetic susceptibility, and magnetization isotherm measurements. Combining a detailed analysis of the magnetic susceptibility and isothermal magnetization, we find that this compound harbors a complicated magnetic phase diagram, and its magnetic moment arrangement appears not to simply follow the fashion as observed in the isostructural counterpart GdIn3(it adopts a conventional type-Cmagnetic structure that belongs to type-IV magnetic space groups). A careful study of the magnetic properties around the antiferromagnetic (AFM)-paramagnetic transition yields the critical exponentsß= 0.309 (0.297),γ= 1.117 (1.038), andδ= 4.617 (4.454), indicating that the tricritical mean field model or the three-dimensional Ising model works for ErIn3's magnetic behaviors and the presence of a long-range AFM interaction therein. Besides, the exchange interaction distanceJ(r) ∼r-4.665as well confirms a long-range magnetic coupling in ErIn3. Our results offer the clues that the magnetic structure varies from one member ofReIn3family to another, and to confirm their electronic features in the AFM phases further experimental and theoretical studies are still desired.

Anisotropic magnetoresistance and electronic features of the candidate topological compound praseodymium monobismuthide.

PrBi, a sister member of the rare-earth monopnictide family, is an excellent candidate for studying extreme magnetoresistance and nontrivial topological electronic states. In this study, we perform angular magnetoresistance measurements as well as bulk and surface band structure calculations on this compound. PrBi's magnetoresistance is revealed to be significantly angle-dependent and shows a fourfold symmetry as always observed in the nonmagnetic isostructural counterparts, including LaSb, LaBi, and LuBi. Its angular magnetoresistance can be reproduced well using the semiclassical two-band model. The deduced parameters suggest that PrBi hosts an elongated electron pocket with a mobility anisotropy of ∼3.13 and is slightly uncompensated in its carrier concentration. Our bulk and surface band structure calculations confirm the anisotropic electronic features. Moreover, we reveal that a nodal-line-shaped surface state appears at the X̄ point, and is associated with the quadratic dispersion along the -X̄ direction, and the linear type-I Dirac dispersion along the X̄-M̄ direction. Owing to the type-I Dirac dispersion feature, PrBi could serve as a promising material platform for studying many unexpected physical properties, such as the highly anisotropic transport and valley polarization of electrons.

The novel HLA-A*02:625 allele was identified in a Chinese bone marrow donor.

HLA-A*02:625 differs from HLA-A*02:06:01:01 by a single nucleotide substitution at position 806 C>T.

Identification of the novel HLA-B*40:333 allele by polymerase chain reaction sequence-based typing.

HLA-B*40:333 differs from HLA-B*40:01:01 by a single nucleotide substitution at position 380 T>C.

Identification of the novel HLA-B*27:04:06 allele in a Chinese bone marrow donor.

HLA-B*27:04:06 differs from HLA-B*27:04:01 by a single-nucleotide substitution at position 396 C > A.

Identification of the novel HLA-B*27:147 allele by polymerase chain reaction sequence-based typing.

HLA-B*27:147 differs from HLA-B*27:04:01 by a single nucleotide substitution at position 523 C>G.

Identification of the novel HLA-DRB1*15:127 allele by polymerase chain reaction sequence-based typing in a Chinese bone marrow donor.

HLA-DRB1*15:127 has 1 nucleotide change from HLA-DRB1*15:01:01:01 at position 308 C>G.

Identification of 2 novel HLA-B alleles, HLA-B*55:02:09 and HLA-B*55:80 in Chinese individuals.

HLA-B*55:02:09 and HLA-B*55:80 differ from HLA-B*55:02:01 by 1 single nucleotide substitution, respectively.

Identification of the novel HLA-B*52:01:27 allele by polymerase chain reaction sequence-based typing.

HLA-B*52:01:27 differs from HLA-B*52:01:01 by a single nucleotide substitution at position 681 C>T.

A novel HLA-C allele, HLA-C*08:128, was identified in a leukemia patient by polymerase chain reaction sequence-based typing.

HLA-C*08:128 shows a substitution C to T at position 704 when compared to HLA-C*08:01:01.

Identification of the novel HLA-B*13:83 allele by polymerase chain reaction sequence-based typing in a Chinese cord blood donor.

HLA-B*13:83 differs from HLA-B*13:01:01 by 2 nucleotide substitutions at positions 103 and 106.

Identification of the novel null allele, HLA-C*01:109N, using polymerase chain reaction sequence-based typing in a Chinese leukemia patient.

HLA-C*01:109N differs from HLA-C*01:02:01 by a single nucleotide substitution at position 683 G > A.

Identification of the novel HLA-DRB1*08:69 allele by polymerase chain reaction sequence-based typing in a Chinese cord blood donor.

HLA-DRB1*08:69 has one nucleotide change from HLA-DRB1*08:03:02 at position 262 G>A.

Prognostic value of ZFP36 and SOCS3 expressions in human prostate cancer

Purpose: ZFP36 ring finger protein (ZFP36) and the suppressor of cytokine signaling 3 (SOCS3) have been reported to, respectively, regulate NF-jB and STAT3 signaling pathways. To better understand the correlation of NF-jB and STAT3 negative regulates pathway, we have investigated the involvement of ZFP36 and SOCS3 expressions in human prostate cancer (PCa). Methods: In the present study, paired patient tissue microarrays were analyzed by immunohistochemistry, and the ZFP36 protein expression was quantitated as immunoreactive scores in patients with PCa. Associations between ZFP36/SOCS3 expression and various clinicopathological features and prognosis of PCa patients were statistically analyzed based on the Taylor database. Then, the functions of ZFP36 and SOCS3 in cancerous inflammation were determined using qPCR and immunohistochemistry in vitro and in vivo. Results: ZFP36 protein expression in PCa tissues was significantly lower than those in non-cancerous prostate tissues (P < 0.05). In mRNA level, ZFP36 and SOCS3 had a close correlation with each other (P < 0.01, Pearson r = 0.848), and its upregulation was both significantly associated with low Gleason score (P < 0.001 and P < 0.001, respectively), negative metastasis (P < 0.001 and P < 0.001, respectively), favorable overall survival (P < 0.001 and P < 0.05, respectively), and negative biochemical recurrence (P < 0.001 and P < 0.001, respectively). Functionally, LPS treatment could lead to the overexpression of ZFP36 and SOCS3 in vitro and vivo. Conclusions: Our data offer the convincing evidence for the first time that the aberrant expressions of ZFP36 and SOCS3 may be involved into the progression and patients’ prognosis of PCa, implying their potentials as candidate markers of this cancer

No disponible

Identification of a novel HLA-B*54:34 allele by polymerase chain reaction sequence-based typing in a Chinese leukemia patient.

HLA-B*54:34 is different from HLA-A*54:01:01 by a single nucleotide substitution at position 343 G>A.

Prognostic value of ZFP36 and SOCS3 expressions in human prostate cancer.

PURPOSE: ZFP36 ring finger protein (ZFP36) and the suppressor of cytokine signaling 3 (SOCS3) have been reported to, respectively, regulate NF-κB and STAT3 signaling pathways. To better understand the correlation of NF-κB and STAT3 negative regulates pathway, we have investigated the involvement of ZFP36 and SOCS3 expressions in human prostate cancer (PCa). METHODS: In the present study, paired patient tissue microarrays were analyzed by immunohistochemistry, and the ZFP36 protein expression was quantitated as immunoreactive scores in patients with PCa. Associations between ZFP36/SOCS3 expression and various clinicopathological features and prognosis of PCa patients were statistically analyzed based on the Taylor database. Then, the functions of ZFP36 and SOCS3 in cancerous inflammation were determined using qPCR and immunohistochemistry in vitro and in vivo. RESULTS: ZFP36 protein expression in PCa tissues was significantly lower than those in non-cancerous prostate tissues (P < 0.05). In mRNA level, ZFP36 and SOCS3 had a close correlation with each other (P < 0.01, Pearson r = 0.848), and its upregulation was both significantly associated with low Gleason score (P < 0.001 and P < 0.001, respectively), negative metastasis (P < 0.001 and P < 0.001, respectively), favorable overall survival (P < 0.001 and P < 0.05, respectively), and negative biochemical recurrence (P < 0.001 and P < 0.001, respectively). Functionally, LPS treatment could lead to the overexpression of ZFP36 and SOCS3 in vitro and vivo. CONCLUSIONS: Our data offer the convincing evidence for the first time that the aberrant expressions of ZFP36 and SOCS3 may be involved into the progression and patients' prognosis of PCa, implying their potentials as candidate markers of this cancer.

Two novel HLA-DQB1*03:03 alleles, HLA-DQB1*03:03:08 and DQB1*03:03:13, were identified in Chinese individuals.

Compared with HLA-DQB1*03:03:02:01, HLA-DQB1*03:03:08 and DQB1*03:03:13 have 330 G>C and 349 T>C changes, respectively.

HLA-C*06:103, a novel allele was identified in a Chinese patient awaiting hematopoietic stem cell transplantation.

HLA-C*06:103 shows four nucleotides difference from that of HLA-C*06:02:01:01.

A novel HLA-A*32 allele, A*32:67 was identified by polymerase chain reaction sequence-based typing in a Chinese individual.

HLA-A*32:67 has a single nucleotide difference at position 286 C>A compared with HLA-A*32:01:01.

Identification of a novel HLA-A*02:06:14 allele by polymerase chain reaction sequence-based typing in a Chinese bone marrow donor.

HLA*02:06:14 differs from HLA-A*02:06:01 by a single nucleotide substitution G > A at position 246.